April 16, 2018 / 6:14 AM / 5 months ago

BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative Metastatic Breast Cancer Presented At AACR

April 16 (Reuters) - AstraZeneca PLC:

* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA® (OLAPARIB) IN GBRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR

* ASTRAZENECA- TRIAL COMPARED LYNPARZA WITH CHEMOTHERAPY FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER, MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below